A Phase 3 trial found Eli Lilly's oral drug orforglipron outperformed oral semaglutide for weight loss and blood sugar control, though it caused more gastrointestinal side effects.
People taking semaglutide for weight loss continued to consume significantly fewer calories after 60 weeks on the medication, ...
A 60-week study found semaglutide helped participants maintain lower calorie intake and lose more weight than placebo, ...
A phase 3 trial found the daily pill orforglipron lowered HbA1c more than oral semaglutide in adults with type 2 diabetes. It ...
The weight loss drugs landscape in the UK underwent a seismic shift on 6 July 2026 when Wegovy – an injectable semaglutide – became the first GLP-1 availab ...
A large head-to-head analysis reveals when outcomes began to diverge and why questions about the drugs’ cardiovascular effects remain unresolved. Semaglutide vs. liraglutide and incidence of diabetes ...
The first generic weight-loss GLP-1 injection Sevmia was recently approved by Health Canada. Here’s what you need to know.
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and ...
Researchers analyzed blood samples from people with HIV treated with semaglutide. Epigenetic clocks showed slower biological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results